Last reviewed · How we verify
Short term androgen deprivation
Short-term androgen deprivation therapy (ADT) temporarily suppresses testosterone production to slow or stop the growth of androgen-dependent prostate cancer cells.
Short-term androgen deprivation therapy (ADT) temporarily suppresses testosterone production to slow or stop the growth of androgen-dependent prostate cancer cells. Used for Intermediate- to high-risk localized prostate cancer (in combination with radiation therapy), Locally advanced prostate cancer.
At a glance
| Generic name | Short term androgen deprivation |
|---|---|
| Also known as | Neoadjuvant and concomitant |
| Sponsor | Fundación de Investigación Biomédica - Hospital Universitario de La Princesa |
| Drug class | Androgen deprivation therapy (ADT) |
| Target | Androgen receptor / testosterone production |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
ADT works by blocking the production or action of androgens (primarily testosterone), which are required for prostate cancer cell proliferation. Short-term ADT is typically administered for 4–6 months in combination with external beam radiation therapy or other treatments in intermediate- to high-risk prostate cancer. This approach aims to reduce tumor burden and improve treatment efficacy while minimizing long-term toxicity associated with prolonged hormone deprivation.
Approved indications
- Intermediate- to high-risk localized prostate cancer (in combination with radiation therapy)
- Locally advanced prostate cancer
Common side effects
- Hot flashes
- Erectile dysfunction
- Fatigue
- Decreased libido
- Gynecomastia
- Bone density loss
- Metabolic syndrome
Key clinical trials
- Non-inferiority Study Comparing Salvage Pelvic Radiotherapy in 25 Fractions (62.5 Gy/25) Versus 20 Fractions (52.5 Gy/20) for Recurrent Prostate Cancer After Surgery. (NA)
- Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer (PHASE3)
- Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging (PHASE3)
- The University of Miami Adapt (UAdapt) Trial (PHASE2)
- Radiation and Androgen Ablation for Prostate Cancer (PHASE1, PHASE2)
- Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabolic Health in Prostate Cancer Patients During Androgen Deprivation Therapy, IMPACT-ADT Trial (PHASE2)
- Strategic Endocrine Therapy and Targeted Radiotherapy for Prostate Cancer (PHASE2)
- The Impact of Androgen Ablation Therapy on Cognitive Functioning and Functional Status in Men With Prostate Cancer Age 65 and Older
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: